Sunday 18 October 2026 Export VNDA’s income statement to Excel — free account

Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024. In the quarter to June 2026, revenue fell 3.92%, EPS fell 126.1%, free cash flow fell 101.0% and total debt rose 2.98%, each against the same quarter a year earlier.

4.03 0.21 −4.95%

Follow VNDA

Alert me

Market cap: $256.4M
P/E: 0.0×
Fwd P/E: −2.6×
Dividend yield: —
F-score: 2/9
Altman Z: 0.72
Beneish M: −3.88
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.82

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	1	5	—	—	—	—	—	—	—

Insider Ownership 5.03%

Capital & Financial Ratios $m

Market Cap 256.36

Revenue 215.72

Net Income (274.85)

Free Cash Flow (153.00)

Net Debt (166.85)

Current Ratio 1.61

Debt/Equity 0.01

P/E ratio 0.00

Fwd P/E (2.61)

P/S ratio 1.13

P/B ratio 1.10

Past 5Y EPS Growth —

This Y EPS Growth 18.98%

Next Y EPS Growth 68.38%

Next Y revenue growth 15.18%

Next 5Y EPS Growth 54.89%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 2.40%

10-year low 10-year high

P/B against its own 10 years 29.89%

10-year low 10-year high

EV/Sales against its own 10 years 1.70%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	388	375	264	170
Receivables	34	47	55	60
Inventory	1	2	2	2
Other	—	—	—	—
	433	439	347	264

	2023	2024	2025	Q'26
Payables	38	39	68	70
ST’ Debt	—	—	—	—
Other	49	61	77	94
	88	100	145	164

Compound Annual Growth %

	10y	5y	3y
Sales	6.99%	(2.73%)	(5.29%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	9.42%	(6.31%)	(14.70%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	52	51	—	—	—
’25	50	53	56	57	216
’24	47	50	48	53	199
’23	62	46	39	45	193
’22	60	64	65	64	254
’21	63	68	70	68	269
’20	58	62	60	68	248

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(50)	(31)	—	—	—
’25	(33)	(15)	(32)	(29)	(109)
’24	8	(7)	(15)	(2)	(16)
’23	32	(13)	(2)	(4)	13
’22	4	6	13	9	32
’21	9	19	9	27	64
’20	(1)	24	9	19	52

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(60)	(31)	—	—	—
’25	(34)	(16)	(32)	(30)	(110)
’24	5	(9)	(15)	(2)	(20)
’23	32	(13)	(2)	(105)	(88)
’22	4	5	13	9	31
’21	9	19	9	26	64
’20	(1)	24	9	18	50

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.82)	(1.04)	—	—	—
’25	(0.50)	(0.46)	(0.38)	(2.39)	(3.74)
’24	(0.07)	(0.08)	(0.09)	(0.08)	(0.33)
’23	0.06	0.03	0.00	(0.04)	0.04
’22	(0.11)	0.05	0.06	0.12	0.11
’21	0.15	0.17	0.14	0.12	0.58
’20	0.01	0.16	0.11	0.15	0.42

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	6.91	11.90	13.75	11.83	7.12	13.14	6.73	3.30	3.46	3.81	Analyst estimates 2026–2028 Powerpack
	High	18.00	18.99	33.44	31.30	16.96	21.86	16.93	8.15	6.75	9.60
People
People	Employees	142	273	273	270	292	278	290	203	203	533
	Revenue/emp, $m	1.03	0.60	0.71	0.84	0.85	0.97	0.88	0.95	0.98	0.41
Income, $m
Income, $m	Revenue	146	165	193	227	248	269	254	193	199	216
	Gross margin, %	83.08	89.19	89.38	89.22	90.59	90.46	90.45	92.32	94.31	93.96
	EBT	(18)	(15)	25	29	32	42	11	6	(23)	(139)
	EBT margin, %	(12.26)	(9.35)	13.12	12.78	12.76	15.77	4.44	3.29	(11.53)	(64.16)
	Net income	(18)	(16)	25	116	23	33	6	3	(19)	(220)
	Depreciation	12	3	1	0	3	4	0	(4)	3	10
Per share, $
Per share, $	Revenue	3.36	3.69	3.79	4.28	4.56	4.84	4.51	3.36	3.42	3.67
	Earnings	(0.41)	(0.35)	0.50	2.17	0.43	0.60	0.11	0.04	(0.33)	(3.74)
	Cash flow	(0.19)	(0.04)	0.59	0.86	0.95	1.16	0.57	0.22	(0.27)	(1.86)
	Capex	(0.03)	(0.04)	(0.50)	(0.02)	(0.03)	(0.01)	(0.01)	(1.76)	(0.08)	(0.02)
	Free cash flow	(0.22)	(0.08)	0.09	0.85	0.92	1.15	0.55	(1.54)	(0.35)	(1.87)
	Book value	3.02	2.94	5.41	7.73	8.33	9.09	9.34	9.50	9.26	5.55
	Shares, m	43	45	51	53	54	56	56	57	58	59
Valuation, ×
Valuation, ×	P/E	0.00	0.00	52.26	7.56	30.56	26.15	61.83	86.26	0.00	0.00
	P/S	4.64	4.23	6.89	3.84	2.88	3.24	1.65	1.35	1.40	2.41
	P/B	5.16	5.31	4.83	2.12	1.58	1.73	0.79	0.48	0.52	1.59
	EV/Sales	3.67	3.36	5.55	2.52	1.45	1.67	(0.15)	(0.63)	(0.47)	1.20
	EV/FCF	(29.44)	(152.03)	232.28	28.72	14.37	11.61	(6.20)	1.07	2.04	(2.35)
Cash, $m
Cash, $m	Operating cash flow	(8)	(2)	30	46	52	64	32	13	(16)	(109)
	Capex	(1)	(2)	(25)	(1)	(2)	(1)	(1)	(101)	(5)	(1)
	Free cash flow	(10)	(4)	5	45	50	64	31	(88)	(20)	(110)
Balance, $m
Balance, $m	Working capital	124	99	246	295	343	404	428	345	339	202
	Total debt	—	—	—	12	11	10	9	—	3	4
	Net debt	(141)	(143)	(257)	(300)	(356)	(423)	(458)	(388)	(371)	(260)
	Shareholders’ equity	131	131	275	411	453	505	527	545	539	327
Returns, %
Returns, %	ROA	(8.51)	(7.49)	9.38	28.33	4.59	5.88	1.02	0.39	(2.90)	(38.51)
	ROIC	0.00	0.00	75.22	12.81	17.55	32.07	5.72	(5.57)	(15.21)	(140.15)
	ROE	(13.63)	(11.85)	12.39	33.67	5.40	6.92	1.22	0.47	(3.49)	(50.93)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ABEO Abeona Therapeutics Inc.	$265.9M	— (loss-making)	— (loss-making)	+225.14% (above 0%: growing)	n/m	+17.11% (above 0%: growing)	63.30%	(119.97%)	Compare
PRLD Prelude Therapeutics Incorporated	$265.0M	— (loss-making)	— (loss-making)	+42.60% (above 0%: growing)	n/m	+40.32% (above 0%: growing)	100.00%	(270.93%)	Compare
CABA Cabaletta Bio, Inc.	$262.8M	— (loss-making)	—	—	n/m	−35.72% (below 0%: shrinking)	0.00%	0.00%	Compare
XFOR X4 Pharmaceuticals, Inc.	$261.8M	— (loss-making)	— (loss-making)	+346.33% (above 0%: growing)	n/m	+13.76% (above 0%: growing)	81.64%	(186.13%)	Compare
RCKT Rocket Pharmaceuticals, Inc.	$259.1M	— (loss-making)	—	—	n/m	+19.16% (above 0%: growing)	0.00%	0.00%	Compare
VNDA Vanda Pharmaceuticals Inc.	$256.4M	— (loss-making)	— (loss-making)	−3.92% (below 0%: shrinking)	n/m	−101.02% (below 0%: shrinking)	92.95%	(126.28%)
IKT Inhibikase Therapeutics, Inc.	$255.4M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−123.23% (below 0%: shrinking)	0.00%	0.00%	Compare
LCTX Lineage Cell Therapeutics, Inc.	$250.5M	— (loss-making)	— (loss-making)	−61.34% (below 0%: shrinking)	n/m	−32.40% (below 0%: shrinking)	100.00%	(834.71%)	Compare
ACIU AC Immune	$249.4M	— (loss-making)	— (loss-making)	+29.66% (above 0%: growing)	n/m	+4.66% (above 0%: growing)	100.00%	(1,321.50%)	Compare
Median of peers	$260.4M	—	—	+36.13%	—	+9.21%	72.47%	(153.05%)

All 614 Biotechnology stocks →

Vanda Pharmaceuticals Inc. (VNDA) key facts

Strength: Vanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024.
Vanda Pharmaceuticals Inc. (VNDA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, VNDA traded at $4.03, a market capitalization of $256.4 million.
Return on equity was −50.9% and debt-to-equity 0.01.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 0.72 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.